Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LGX818 + MEK162 followed by genotype-guided triple targeted therapy after progression in BRAF V600 melanoma
NL-OMON45032Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib, binimetinib, buparlisib, infigratinib, capmatinib and 1 more in melanoma and cutaneous malignancy (7 arms), sponsored by Pfizer. Primary endpoint: Overall response rate. Started Feb 2015; status: active, not recruiting.
02
Drugs
encorafenibbinimetinibbuparlisibinfigratinibcapmatinib
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON45032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45032.